Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials
Godela Brosnahan(University of Colorado Denver), Peter C. Harris(Mayo Clinic), James E. Bost, Kaleab Z. Abebe(University of Pittsburgh), Neil J. Halin, Pardeep Mittal(Emory University), Franz T. Winklhofer(University of Kansas), Jesse Wei, Diego R. Martín(Emory University), Erick M. Remer(Cleveland Clinic), Iván Pedrosa(The University of Texas Southwestern Medical Center), Peter G. Czarnecki(Beth Israel Deaconess Medical Center), Louis H. Wetzel(University of Kansas), Nayana Patel, Amirali Masoumi, Alan S.L. Yu(University of Kansas Medical Center), Frederic F. Rahbari-Oskoui(Emory University), Ziad Zoghby(Mayo Clinic), Dana C. Miskulin(Tufts University), Vicente E. Torres(Mayo Clinic in Arizona), Cass Kelleher, Michael F. Flessner, Ronald D. Perrone(Tufts Medical Center), Berenice Y. Gitomer(University of Colorado Denver), Theodore I. Steinman(Beth Israel Deaconess Medical Center), Marie C. Hogan(Mayo Clinic), William E. Braun(Cleveland Clinic), Connie Wang, Charity G. Moore(University of Pittsburgh Medical Center), Robert W. Schrier(University of Denver), James F. Glockner(Mayo Clinic), Bernard King, Kyongtae T. Bae(Mallinckrodt (United States)), Jared J. Grantham(National Institutes of Health), Arlene B. Chapman(Emory University)
Cited by 49
Related Papers
K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
|Data Archiving and Networked Services (DANS)|2002|11.7k
National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification
|Annals of Internal Medicine|2003|4.6k
Tolvaptan, a Selective Oral Vasopressin V <sub>2</sub> -Receptor Antagonist, for Hyponatremia
|New England Journal of Medicine|2006|1.2k
Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
|Kidney International|2015|602
Role of Cardiac Magnetic Resonance Imaging in the Detection of Cardiac Amyloidosis
|JACC. Cardiovascular imaging|2010|544